Vaccine composition

US9233151B2 · kind B2 · utility

Assignee

• GLAXOSMITHKLINE BIOLOGICALS SA · BE

Inventors

• Dominique Boutriau · Rixensart, BE
• Carine Capiau · Rixensart, BE
• Pierre Desmons · Nivelles, BE
• Dominique Ingrid Lemoine · Rixensart, BE
• Jan Poolman · Broek in Waterland, NL

Key dates

• Filing date: Apr 4, 2012
• Grant date: Jan 12, 2016
• Expiry date: Apr 4, 2032

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A multi-valent vaccine composition is described comprising a conjugate of the capsular polysaccharide of H. influenzae b not adsorbed onto an aluminum adjuvant salt, and two or more further bacterial polysaccharides. A multi-valent vaccine composition is also described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, Hepatitis B surface antigen, a conjugate of the capsular polysaccharide of H. influenzae b, and a conjugate of a capsular polysaccharide of N. meningitidis type A or C (or both). Furthermore, a multi-valent vaccine composition is described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, and a low dose of a conjugate of the capsular polysaccharide of H. influenzae b.